Proteomic analysis of Crow-Fukase syndrome

Crow-Fukase 综合征的蛋白质组学分析

基本信息

批准号：
17590888
负责人：
HASHIGUCHI Teruto
金额：
$ 2.24万
依托单位：
Kagoshima University
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
2005
资助国家：
日本
起止时间：
2005 至 2006
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-17590888/
关键词：
Crow-Fukase syndrome POEMS syndrome proteome proteomics peptidome VEGF brain nerve Syndrome

项目摘要

Objective : This study aimed to establish a diagnostic method for detecting what molecules have been degraded and what is going to progress next, by comprehensively and rapidly identifying peptide fragments in the patient's serum throughout subsequent pathological stages, thereby developing a diagnostic method that contributes to determining the appropriate direction of strategies for assessment of the pathological condition, nutritional support, and drug treatment. Methods : New proteome analysis technology, developed by Protosera Inc., was applied for the differential profiling of untreated serum samples from normal subjects and the same patient with Crow-Fukase Syndrome (POEMS Syndrome),an intractable inflammatory disorder, in the stable (at the time of diagnosis),exacerbation, DIC, and MOF stages, and MS/MS de novo sequencing of significantly different MS peaks was performed. A similar analysis was conducted of untreated serum samples from normal subjects and patients with six different types of early cancer. Results : We identified 94 low-molecular-weight peptide fragments that characteristically appeared in the DIC and MOF stages. These peptide fragments were derived from carrier proteins, such as transthyretin and protease inhibitors such as α1-antitrypsin. Moreover, some of these 94 peptide fragments coincided with the peptide fragment peaks that were characteristically observed in the respective early cancer patients. Discussion : The patterns of low-molecular-weight peptide fragments that appear in the blood reflect the activation of proteases characterizing the biological environment, including that of normal subjects and patients with cancer, DIC, or MOF, thereby providing valuable information on pathological conditions. We consider that these results will lead to the development of a method that contributes to determining the appropriate direction of strategies for pathological condition diagnosis, nutritional support, and drug treatment.

目的：这项研究旨在建立一种诊断方法，用于检测哪些分子降解以及接下来要进行的进展，通过全面，迅速识别在随后的过程学阶段中患者血清中患者血清中的肽片段，从而开发出一种诊断方法，从而为确定病理学治疗的策略促进病理学的策略，并进行病理学上的治疗，营养学，营养学，营养学，以及营养学治疗的适当方向。方法：由Protosera Inc.开发的新蛋白质组分析技术用于在正常受试者中未经处理的血清样品的差异分析，以及同一患有乌鸦 - - 富氧酶综合征（Poems综合征）的患者，一种可怕的炎症性疾病，一种稳定的炎症性疾病（一种稳定时（诊断时），DEC和MS MS/MS/MS/MS/MS/MS/MS/MS/MS/MS/MS/MS/MS/MS/MS/MS/MS/MS/MS/MS/MS STEMORIANS NOVEND NEVING STEMING NOVERIAN STEMORIAN和MS MS/MS/MS/MS/MS。执行。从正常受试者和患有六种不同类型的早期癌症患者的未经治疗的血清样品进行了类似的分析。结果：我们确定了94个低分子量的肽片段，这些肽片段特征在DIC和MOF阶段出现。这些肽片段源自载体蛋白，例如经硫代蛋白和蛋白抑制剂，例如α1-抗抗蛋白酶。此外，这94个肽片段中的一些与肽片段峰同时观察到了各自早期癌症患者。讨论：出现在血液中的低分子量肽片段的模式反映了表征生物学环境的蛋白质的激活，包括正常受试者和患有癌症，DIC或MOF的患者的蛋白质，从而提供了有关患者状况的宝贵信息。我们认为这些结果将导致开发一种方法，该方法有助于确定病理状况诊断，营养支持和药物治疗的适当策略方向。